Chondrosarcoma Overview

Save information for later
Sign Up

Learn About Chondrosarcoma

View Main Condition: Brain Tumor

What is the definition of Chondrosarcoma?
Chondrosarcoma is a rare, slow-growing form of bone cancer that develops in the bones or the cartilage. The cartilage is the connective tissue from which most bones develop. Chondrosarcomas appear in bones or cartilage at the base of the skull, arms, scapula, ribs, pelvis, knee, femur (thighbone), or tibia.
What are the symptoms of Chondrosarcoma?
Symptoms of chondrosarcoma depend on the cartilage or bone that is involved and include the appearance of a large mass on the affected bone, swelling and pressure surrounding the mass, muscle wasting, gradually increasing pain not relieved with rest, constant pain that worsens at night, and fracture of the affected bone. A chondrosarcoma that appears on the spine may cause weakness, numbness, and an inability to control the release of urine (incontinence) or bowels.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Chondrosarcoma?
Treatment for chondrosarcoma depends on a patient’s age, overall health, medical history, the stage and location of the cancer, and may include surgery to remove the tumor, bone reconstructive surgery, amputation, radiation therapy, chemotherapy, and physical therapy.
Who are the top Chondrosarcoma Local Doctors?
Melissa A. Burgess
Elite in Chondrosarcoma
Dr. Melissa A. Burgess
Hematology Oncology
Elite in Chondrosarcoma
Dr. Melissa A. Burgess
Hematology Oncology

UPMC Hillman Cancer Center

5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
412-623-4759
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Melissa Burgess, MD, is an assistant professor at the University of Pittsburgh School of Medicine and a medical oncologist. She specializes in the treatment of soft tissue and bone sarcomas and Merkel cell carcinoma. Dr. Burgess is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Merkel Cell Carcinoma, Liposarcoma, Chondrosarcoma, and Gamma Knife Radiosurgery.

Brian E. Brigman
Elite in Chondrosarcoma
Dr. Brian E. Brigman
Surgical Oncology
Elite in Chondrosarcoma
Dr. Brian E. Brigman
Surgical Oncology

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
919-681-6900
Experience:
31+ years
Languages Spoken:
English
See accepted insurances

As an orthopaedic oncologist, I am passionate about providing the best diagnostic and therapeutic surgical care for patients with benign or malignant bone or soft tissue tumors of the musculoskeletal system. As the director of the Sarcoma program at the Duke Cancer Institute, my passion is building our team to provide the best clinical care and basic scientific, translational and clinical research to serve our patients. Dr. Brigman is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Bone Tumor, Chondrosarcoma, Bone Graft, and Hip Replacement.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Chondrosarcoma
Dr. Anthony Conley
Oncology
Elite in Chondrosarcoma
Dr. Anthony Conley
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Conley is an Oncologist in Houston, Texas. Dr. Conley is rated as an Elite provider by MediFind in the treatment of Chondrosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Chondrosarcoma, Alveolar Soft Part Sarcoma, Liposarcoma, and Salpingo-Oophorectomy.

View All Doctors
What are the latest Chondrosarcoma Clinical Trials?
A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors
Who is this study for: Patients with advanced solid tumors
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug, Biological
Study Drugs: IPN60090, Pembrolizumab
Study Phase: Phase 1

Summary: To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resect...

View All Clinical Trials